NervGen Announces Leadership Transition to Support Strategic Growth and Expansion

Core Insights - NervGen Pharma Corp. announced a leadership transition with Dr. Adam Rogers appointed as Interim CEO following positive results from the chronic spinal cord injury trial for its candidate NVG-291 [1][2][3] - The company is entering a critical phase of development for NVG-291, which has shown strong efficacy signals in the chronic cohort of the CONNECT SCI study [3][5] Company Overview - NervGen is a clinical-stage biotechnology company focused on developing therapies for spinal cord injury and other nervous system disorders [1][5] - The company holds exclusive worldwide rights to NVG-291, a therapeutic peptide aimed at promoting nervous system repair, which has received Fast Track designation from the FDA and Orphan Designation from the EMA [4][5] Leadership Transition - Mike Kelly has stepped down as President and CEO, with Dr. Adam Rogers taking over as Interim CEO, emphasizing the need for strategic growth and regulatory engagement [2][3] - Dr. Rogers expressed gratitude for Kelly's leadership during a pivotal time and highlighted the importance of the recent trial results for future growth [3][5] Clinical Development - The chronic cohort of the CONNECT SCI study demonstrated that NVG-291 met its primary endpoint and showed strong trends in functional assessments [5][6] - Ongoing analysis of data from the chronic cohort is being conducted, while enrollment in the subacute cohort continues [6]